Equities

Golden Throat Holdings Group Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Golden Throat Holdings Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)3.20
  • Today's Change0.01 / 0.31%
  • Shares traded465.00k
  • 1 Year change-3.03%
  • Beta0.1811
Data delayed at least 15 minutes, as of Feb 06 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Golden Throat Holdings Group Co Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceutical, healthcare food and other products. The Company has three products categories that include Golden Throat Lozenges (Over the Counter), which is designed to relieve symptoms of sore and dry throat and hoarse voice caused by acute pharyngitis, Golden Throat Series Products including Dule Lozenges and others, and other products including Yinxingye Tablet, Golden Throat Intestinal Series and others. The Company mainly conducts its business in the domestic and overseas markets.

  • Revenue in HKD (TTM)1.10bn
  • Net income in HKD301.74m
  • Incorporated2014
  • Employees842.00
  • Location
    Golden Throat Holdings Group Co LtdNo. 28 Fengxiang RoadLIUZHOU ChinaCHN
  • Phone+86 7 722825718
  • Websitehttps://www.gxjsz.com/en/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
3D Medicines Inc504.64m-189.64m1.19bn183.00--1.48--2.36-0.7741-0.77412.063.120.37287.536.782,642,071.00-14.79---21.47--92.11---39.68--1.59--0.205---29.81--65.19------
Beijing Biostar Pharmaceuticals Co Ltd-100.00bn-100.00bn1.26bn147.00------------------------------------------------7.85--24.19------
Canbridge Pharmaceuticals Inc70.40m-153.19m1.61bn45.00------22.87-0.3606-0.36060.1657-1.080.3531.193.511,050,803.00-76.80-120.49---212.9564.4062.24-217.58-1,040.820.0371-36.43-----17.27125.21-16.84---69.90--
Cutia Therapeutics281.73m-531.51m1.74bn298.00--1.81--6.19-1.69-1.690.89662.650.19082.555.57846,035.70-36.00---44.42--34.92---188.66--2.92--0.2774--103.17--77.91------
Dawnrays Pharmaceutical (Holdings) Ltd1.25bn198.60m1.79bn1.12k9.020.48126.081.430.13190.13190.83182.470.28092.477.961,059,112.004.3610.985.0713.7545.7655.5215.5332.764.21--0.002831.01-7.892.2273.2917.2017.132.69
Zhaoke Ophthalmology Ltd39.79m-313.22m1.82bn270.00--0.9472--45.86-0.5662-0.56620.0723.520.01591.389.25135,350.70-12.50-38.02-14.65-41.7949.28---787.13-4,412.894.36-29.830.1373--269.73--38.32--18.80--
SinoMab Bioscience Ltd0.00-162.45m2.18bn61.00--6.91-----0.150-0.1500.000.22730.00----0.00-18.46-22.26-24.62-25.68-------3,832.94---7.820.6265--48.42--23.85---0.376--
Jbm (Healthcare) Ltd812.98m216.39m2.21bn412.0010.122.057.972.720.26570.26570.99841.310.51113.765.052,913,918.0014.096.5717.007.8356.7647.8227.5616.602.41--0.248653.4020.6515.4451.2036.9035.96--
Golden Throat Holdings Group Co Ltd1.10bn301.74m2.36bn842.007.821.746.952.140.40810.40811.491.840.4672.295.321,261,555.0012.7811.7121.0216.7576.4273.0827.3725.871.7321.950.361694.6723.268.2527.3713.71-12.2734.38
Essex Bio-Technology Ltd1.73bn313.18m2.36bn1.43k7.571.046.381.360.55080.55083.054.010.55962.962.841,196,360.0010.1010.2813.5613.6289.5087.7318.0518.701.82--0.113517.49-3.875.4711.610.3101-7.477.14
Hangzhou Jiuyuan Genetic Biopharm Co Ltd1.47bn138.91m2.43bn1.63k15.581.3713.131.660.64310.64317.197.330.75091.552.17953,516.407.10--8.88--81.67--9.45--4.0346.310.1058--6.35--15.72------
Jacobson Pharma Corporation Ltd1.53bn302.58m2.50bn1.79k8.231.125.541.630.15190.15190.76981.120.42992.549.06876,757.008.484.8310.296.1744.3041.2619.7314.850.902310.210.28657.097.430.069143.097.0524.0914.87
Data as of Feb 06 2026. Currency figures normalised to Golden Throat Holdings Group Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.60%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 08 Jan 20263.58m0.48%
AXA Investment Managers UK Ltd.as of 31 Dec 2025705.00k0.10%
Schroder Investment Management Ltd.as of 31 Dec 202457.44k0.01%
DFA Australia Ltd.as of 30 Nov 202534.39k0.01%
Dimensional Fund Advisors Ltd.as of 30 Nov 202516.51k0.00%
Connor, Clark & Lunn Investment Management Ltd.as of 30 Jun 20257.50k0.00%
More ▼
Data from 30 Sep 2025 - 30 Sep 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.